Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.63 0.63

FILE 'MEDLINE' ENTERED AT 16:56:04 ON 07 JUN 2004

FILE 'USPATFULL' ENTERED AT 16:56:04 ON 07 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:56:04 ON 07 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:56:04 ON 07 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:56:04 ON 07 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 16:56:04 ON 07 JUN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 16:56:04 ON 07 JUN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

=> s efp () binding
L1 1 EFP (W) BINDING

=> s efp
L2 679 EFP

=> s l2 and binding
L3 112 L2 AND BINDING

=> s l3 and increase binding
L4 0 L3 AND INCREASE BINDING

=> s l3 and increase
L5 58 L3 AND INCREASE

=> s l5 and compound
L6 44 L5 AND COMPOUND

=> s (L16 protein)
MISSING OPERATOR L16 PROTEIN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s "l16 protein"
L7 8 "L16 PROTEIN"

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 8 MEDLINE on STN
TI Identification of the yeast nuclear gene for the mitochondrial homologue of bacterial ribosomal protein L16.
AB An open reading frame encoding a member of the L16 family of ribosomal proteins is adjacent to the URA7 gene on the left arm of chromosome II in

Saccharomyces cerevisiae. The predicted L16-like polypeptide is basic (pl 11.12), contains 232 amino acids (26.52 kDa) and has 36% amino acid sequence identity to E. coli L16. Immunoblot analysis with polyclonal antibodies to the L16-like polypeptide showed specific cross-reaction with a 22,000 Mr mitochondrial polypeptide that co-sediments with the large subunit of the mitochondrial ribosome in sucrose density gradients. The levels of the L16 mRNA and protein varied in response to carbon source. In [rho degree] cells lacking mitochondrial rRNA, the L16 mRNA accumulated at normal levels, but the protein was barely detectable, indicating RNA-dependent accumulation of the **L16 protein**. Gene disruption experiments demonstrated that the yeast mitochondrial L16 is an essential ribosomal protein in vivo.

ACCESSION NUMBER: 96017770 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7478995
TITLE: Identification of the yeast nuclear gene for the mitochondrial homologue of bacterial ribosomal protein L16.
AUTHOR: Pan C; Mason T L
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst 01003, USA.
SOURCE: Nucleic acids research, (1995 Sep 25) 23 (18) 3673-7. Journal code: 0411011. ISSN: 0305-1048.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-X78214
ENTRY MONTH: 199511
ENTRY DATE: Entered STN: 19960124
Last Updated on STN: 19960124
Entered Medline: 19951124

L7 ANSWER 2 OF 8 MEDLINE on STN
TI Localization of Saccharomyces cerevisiae ribosomal protein L16 on the surface of 60 S ribosomal subunits by immunoelectron microscopy.
AB Antibodies raised against a trpE-L16 fusion protein expressed in Escherichia coli were used to examine immunological relatedness between Saccharomyces cerevisiae ribosomal protein L16 and ribosomal proteins from eubacteria, halobacteria, methanogens, eocytes, and other eukaryotes. Homologues of L16 also were identified by searches of sequence data bases. Among the bacterial proteins that are immunologically related and similar in sequence to L16 are ribosomal proteins that bind 5 S rRNA. **L16 protein** fused near its carboxyl terminus to E. coli beta-galactosidase could assemble into functional yeast 60 S ribosomal subunits. The RPL16A-lacZ gene fusion partially complemented the slow growth or lethality of mutants containing null alleles of one or both RPL16 genes, respectively. L16-beta-galactosidase fusion protein cosedimented with ribosomes and polyribosomes, and remained associated with high salt-washed ribosomes. Monoclonal antibodies against beta-galactosidase were used to map the location of L16-beta-galactosidase on the surface of the 60 S subunit by immunoelectron microscopy. L16 was localized near the top surface of the central protuberance, where the 60 S subunit potentially contacts the 40 S subunit. This is similar to the location of the bacterial homologues of L16 in 50 S ribosomal subunits.

ACCESSION NUMBER: 94171788 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7510288
TITLE: Localization of Saccharomyces cerevisiae ribosomal protein L16 on the surface of 60 S ribosomal subunits by immunoelectron microscopy.
AUTHOR: Tsay Y F; Shankweiler G; Lake J; Woolford J L Jr
CORPORATE SOURCE: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213.
CONTRACT NUMBER: CA-01000 (NCI)
GM-24034 (NIGMS)
GM-28301 (NIGMS)

SOURCE: Journal of biological chemistry, (1994 Mar 11) 269 (10) 7579-86.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199404
ENTRY DATE: Entered STN: 19940420
Last Updated on STN: 19960129
Entered Medline: 19940412

L7 ANSWER 3 OF 8 MEDLINE on STN
TI Depletion of Saccharomyces cerevisiae ribosomal protein L16 causes a decrease in 60S ribosomal subunits and formation of half-mer polyribosomes.
AB We constructed yeast strains containing deletion-insertion null alleles of the RPL16A or RPL16B genes encoding the 60S ribosomal subunit protein L16 to determine the role of L16 in the synthesis and function of ribosomes. Strains lacking a functional RPL16A gene grow as rapidly as wild type, whereas those containing a null allele of RPL16B grow more slowly than wild type. RNA analysis using RPL16 probes revealed that both RPL16 genes are transcribed and that RPL16B transcripts accumulate to twice the level of RPL16A transcripts. No evidence was obtained for the occurrence of dosage compensation at the level of RPL16 mRNA accumulation in either mutant. Strains lacking both RPL16 genes are apparently inviable, demonstrating that L16 is an essential yeast ribosomal protein. Introduction of an extra copy of either RPL16 gene into rpl16b mutants restored wild-type growth rates, indicating that the two forms of the **L16 protein** are interchangeable. rpl16 mutants are deficient in 60S ribosomal subunits relative to 40S subunits. 43S preinitiation complexes accumulate in half-mer polyribosomes in the absence of sufficient 60S subunits. We postulate that the slow-growth phenotype of rpl16 mutants results from the perturbation of initiation of protein synthesis.
ACCESSION NUMBER: 88196881 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3282992
TITLE: Depletion of Saccharomyces cerevisiae ribosomal protein L16 causes a decrease in 60S ribosomal subunits and formation of half-mer polyribosomes.
AUTHOR: Rotenberg M O; Moritz M; Woolford J L Jr
CORPORATE SOURCE: Department of Biological Sciences, Carmegie Mellon University, Pittsburgh, Pennsylvania 15213.
CONTRACT NUMBER: CA-01000 (NCI)
GM-08067 (NIGMS)
GM-28301 (NIGMS)
SOURCE: Genes & development, (1988 Feb) 2 (2) 160-72.
Journal code: 8711660. ISSN: 0890-9369.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198806
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19880602

L7 ANSWER 4 OF 8 USPATFULL on STN
TI Elongation factor P (EFP) and assays and antimicrobial treatments related to the same
AB Disclosed are novel methods of using elongation factor p (efp) and related constituents of ribosomal complexes which comprise efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of

identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:26250 USPATFULL
TITLE:	Elongation factor P (EFP) and assays and antimicrobial treatments related to the same
INVENTOR(S):	Marotti, Keith R., Kalamazoo, MI, United States Poorman, Roger A., Kalamazoo, MI, United States Wells, Peter A., Kalamazoo, MI, United States Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S):	Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-322732, filed on 28 May 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Cochrane Carlson, Karen
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	O'Connor, P.C., Cozen
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Identification of the yeast nuclear gene for the mitochondrial homologue of bacterial ribosomal protein L16.

AB An open reading frame encoding a member of the L16 family of ribosomal proteins is adjacent to the URA7 gene on the left arm of chromosome II in Saccharomyces cerevisiae. The predicted L16-like polypeptide is basic (pl 11.12), contains 232 amino acids (26.52 kDa) and has 36% amino acid sequence identity to E.coli L16. Immunoblot analysis with polyclonal antibodies to the L16-like polypeptide showed specific cross-reaction with a 22 000 Mr mitochondrial polypeptide that co-sediments with the large subunit of the mitochondrial ribosome in sucrose density gradients. The levels of the L16 mRNA and protein varied in response to carbon source. In [rho°] cells lacking mitochondrial rRNA, the L16 mRNA accumulated at normal levels, but the protein was barely detectable, indicating RNA-dependent accumulation of the **L16 protein**. Gene disruption experiments demonstrated that the yeast mitochondrial L16 is an essential ribosomal protein in vivo.

ACCESSION NUMBER:	95298591 EMBASE
DOCUMENT NUMBER:	1995298591
TITLE:	Identification of the yeast nuclear gene for the mitochondrial homologue of bacterial ribosomal protein L16.

AUTHOR: Pan C.; Mason T.L.
CORPORATE SOURCE: Dept Biochem and Molecular Biology, Program Molecular Cellular Biology, University Massachusetts,Amherst, MA 01003, United States
SOURCE: Nucleic Acids Research, (1995) 23/18 (3673-3677).
ISSN: 0305-1048 CODEN: NARHAD
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 6 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Localization of Saccharomyces cerevisiae ribosomal protein L16 on the surface of 60 S ribosomal subunits by immunoelectron microscopy.
AB Antibodies raised against a trpE-L16 fusion protein expressed in Escherichia coli were used to examine immunological relatedness between Saccharomyces cerevisiae ribosomal protein L16 and ribosomal proteins from eubacteria, halobacteria, methanogens, eocytes, and other eukaryotes. Homologues of L16 also were identified by searches of sequence data bases. Among the bacterial proteins that are immunologically related and similar in sequence to L16 are ribosomal proteins that bind 5 S rRNA. **L16 protein** fused near its carboxyl terminus to E. coli β-galactosidase could assemble into functional yeast 60 S ribosomal subunits. The RPL16A-lacZ gene fusion partially complemented the slow growth or lethality of mutants containing null alleles of one or both RPL16 genes, respectively. L16-β-galactosidase fusion protein cosedimented with ribosomes and polyribosomes, and remained associated with high salt-washed ribosomes. Monoclonal antibodies against β-galactosidase were used to map the location of L16-β-galactosidase on the surface of the 60 S subunit by immunoelectron microscopy. L16 was localized near the top surface of the central protuberance, where the 60 S subunit potentially contacts the 40 S subunit. This is similar to the location of the bacterial homologues of L16 in 50 S ribosomal subunits.
ACCESSION NUMBER: 94204625 EMBASE
DOCUMENT NUMBER: 1994204625
TITLE: Localization of Saccharomyces cerevisiae ribosomal protein L16 on the surface of 60 S ribosomal subunits by immunoelectron microscopy.
AUTHOR: Tsay Y.-F.; Shankweiler G.; Lake J.; Woolford Jr. J.L.
CORPORATE SOURCE: Department of Biological Sciences, Carnegie Mellon University,Pittsburgh, PA 15213, United States
SOURCE: Journal of Biological Chemistry, (1994) 269/10 (7579-7586).
ISSN: 0021-9258 CODEN: JBCHA3
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
LANGUAGE: English
SUMMARY LANGUAGE: English

L7 ANSWER 7 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Novel three dimensional structure of Thermus thermophilus 70S ribosome resolved using x-ray crystallography upto 5.5 Angstroms resolution, useful for screening and designing compounds that alter ribosome function.
AN 2002-713237 [77] WPIDS
AB WO 200246392 A UPAB: 20021129
NOVELTY - A three dimensional structure of Thermus thermophilus 70S ribosome resolved using x-ray crystallography upto 5.5 Angstrom resolution, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method (M1) of identifying a compound that binds to a bacterial 70S ribosome or its portion, comprising:

(a) designing a compound based upon a three-dimensional structure of the bacterial 70S ribosome, where the structure co-ordinates are given in the specification;

(b) providing the compound;

(c) contacting the compound with the bacterial 70S ribosome or its portion; and

(d) determining whether the compound binds to the bacterial 70S ribosome or its portion; and

(2) a computer system comprising a memory comprising X-ray crystallographic structure co-ordinates defining at least a portion of a bacterial 70S ribosome, the structure co-ordinates determined from a crystal of a bacterial 70S ribosome; and a processor in electrical communication with the memory; where the processor generates a molecular model having a three dimensional shape representative of at least a portion of the bacterial 70S ribosome.

USE - The 70S ribosome 3D structure can be used to screen and design compounds that bind to sites on the 70S ribosome and that alter the ribosome function.

Dwg.0/21

ACCESSION NUMBER: 2002-713237 [77] WPIDS
DOC. NO. CPI: C2002-202094
TITLE: Novel three dimensional structure of Thermus thermophilus 70S ribosome resolved using x-ray crystallography upto 5.5 Angstroms resolution, useful for screening and designing compounds that alter ribosome function.
DERWENT CLASS: B04 D16
INVENTOR(S): BAUCOM, A E; CATE, J H D; DALLAS, A; LANCASTER, L; LIEBERMAN, K; NOLLER, H F; YUSUPOV, M M; YUSUPOVA, G Z
PATENT ASSIGNEE(S): (REGC) UNIV CALIFORNIA; (BAUC-I) BAUCOM A E; (CATE-I) CATE J H D; (DALL-I) DALLAS A; (LANC-I) LANCASTER L; (LIEB-I) LIEBERMAN K; (NOLL-I) NOLLER H F; (YUSU-I) YUSUPOV M M; (YUSU-I) YUSUPOVA G Z
COUNTRY COUNT: 99
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002046392	A2	20020613	(200277)*	EN	528
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2002041614	A	20020618	(200280)		
US 2002188108	A1	20021212	(200301)		
EP 1351982	A2	20031015	(200368)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2002046392	A2		WO 2001-US47975	20011210
AU 2002041614	A		AU 2002-41614	20011210
US 2002188108	A1	Provisional	US 2000-254603P	20001209
		Provisional	US 2001-278013P	20010322
		Provisional	US 2001-294394P	20010530
			US 2001-13379	20011210
EP 1351982	A2		EP 2001-988295	20011210
			WO 2001-US47975	20011210

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002041614	A Based on	WO 2002046392
EP 1351982	A2 Based on	WO 2002046392

PRIORITY APPLN. INFO: US 2001-294394P 20010530; US
2000-254603P 20001209; US
2001-278013P 20010322; US
2001-13379 20011210

L7 ANSWER 8 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Identifying a compound which modulates the activity of prokaryotic elongation factor p (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with a compound and determining if efp activity is modified.
AN 2000-524303 [47] WPIDS
AB WO 200045177 A UPAB: 20000925
NOVELTY - A method (M1) for identifying a compound which modulates the activity of efp comprises contacting efp with a compound and determining whether the compound modifies activity of efp.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell containing efp with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates efp activity comprising:

(a) contacting a composition comprising efp, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of efp, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to efp in association with the 30S subunit or 70S ribosome or interferes with the binding of efp and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell or composition containing efp with a detectably labelled oxazolidinone compound known to bind efp;

(b) contacting the composition or cell with an unlabelled compound; and

(c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates efp but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic efp by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic efp, the 30S subunit, 50S subunit, 70S ribosome or **L16 protein** comprising
contacting the efp or cell or cell preparation containing the efp, the 30S subunit, 50S subunit, 70S ribosome or **L16 protein** with
an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS
DOC. NO. NON-CPI: N2000-387540
DOC. NO. CPI: C2000-155724
TITLE: Identifying a compound which modulates the activity of prokaryotic elongation factor p (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with a compound and determining if efp activity is modified.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN; (PHAA) PHARMACIA & UPJOHN CO
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		
EP 1147422	A1	20011024	(200171)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002535680	W	20021022	(200301)		63
US 6511813	B1	20030128	(200311)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2000045177	A1		WO 1999-US12073	19990528
AU 9942246	A		AU 1999-42246	19990528
EP 1147422	A1		EP 1999-926086	19990528
			WO 1999-US12073	19990528
JP 2002535680	W		WO 1999-US12073	19990528
			JP 2000-596378	19990528
US 6511813	B1	Provisional	US 1999-117473P	19990127
		Div ex	US 1999-322732	19990528
			US 2000-704321	20001102

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 2000045177
EP 1147422	A1 Based on	WO 2000045177
JP 2002535680	W Based on	WO 2000045177

PRIORITY APPLN. INFO: US 1999-117473P 19990127; US
1999-322732 19990528; US
2000-704321 20001102

=> d his

(FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
ENTERED AT 16:56:04 ON 07 JUN 2004
L1 1 S EFP () BINDING
L2 679 S EFP
L3 112 S L2 AND BINDING
L4 0 S L3 AND INCREASE BINDING
L5 58 S L3 AND INCREASE
L6 44 S L5 AND COMPOUND
L7 8 S "L16 PROTEIN"

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 1 USPATFULL on STN
TI Elongation factor P (EFP) and assays and antimicrobial treatments related to the same
AB Disclosed are novel methods of using elongation factor p (efp) and related constituents of ribosomal complexes which comprise efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:26250 USPATFULL
TITLE: Elongation factor P (EFP) and assays and antimicrobial treatments related to the same
INVENTOR(S): Marotti, Keith R., Kalamazoo, MI, United States
Poorman, Roger A., Kalamazoo, MI, United States
Wells, Peter A., Kalamazoo, MI, United States
Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-322732, filed on 28 May 1999

```
                              NUMBER         DATE
                     ------------------ --------
PRIORITY INFORMATION:   US 1999-117473P    19990127 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Cochrane Carlson, Karen
ASSISTANT EXAMINER:     Robinson, Hope A.
LEGAL REPRESENTATIVE:   O'Connor, P.C., Cozen
NUMBER OF CLAIMS:       9
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:             1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
     ENTERED AT 16:56:04 ON 07 JUN 2004
L1             1 S EFP () BINDING
L2           679 S EFP
L3           112 S L2 AND BINDING
L4             0 S L3 AND INCREASE BINDING
L5            58 S L3 AND INCREASE
L6            44 S L5 AND COMPOUND
L7             8 S "L16 PROTEIN"

=> s putative efp
L8             0 PUTATIVE EFP

=> s putative efp?
L9             0 PUTATIVE EFP?

=> s efp?
EFP? IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s oxaxolidinone
L10           16 OXAXOLIDINONE

=> s eperezolid
L11          179 EPEREZOLID

=> s linezolid
L12         2222 LINEZOLID

=> s l11 and l6
L13            1 L11 AND L6

=> d l13 ti abs ibib tot

L13  ANSWER 1 OF 1  USPATFULL on STN
TI     Elongation factor P (EFP) and assays and antimicrobial
       treatments related to the same
AB     Disclosed are novel methods of using elongation factor p (efp)
       and related constituents of ribosomal complexes which comprise
       efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the
       70S initiation complex, and related proteins, cofactors and enzymes.
       Methods of identifying compounds which modulate prokaryotic elongation
       factor p and modify cell function are described. Both in vitro and in
```

vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:26250 USPATFULL
TITLE:	Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
INVENTOR(S):	Marotti, Keith R., Kalamazoo, MI, United States Poorman, Roger A., Kalamazoo, MI, United States Wells, Peter A., Kalamazoo, MI, United States Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S):	Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-322732, filed on 28 May 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Cochrane Carlson, Karen
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	O'Connor, P.C., Cozen
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS' ENTERED AT 16:56:04 ON 07 JUN 2004

L1	1	S EFP () BINDING
L2	679	S EFP
L3	112	S L2 AND BINDING
L4	0	S L3 AND INCREASE BINDING
L5	58	S L3 AND INCREASE
L6	44	S L5 AND COMPOUND
L7	8	S "L16 PROTEIN"
L8	0	S PUTATIVE EFP
L9	0	S PUTATIVE EFP?
L10	16	S OXAXOLIDINONE
L11	179	S EPEREZOLID
L12	2222	S LINEZOLID
L13	1	S L11 AND L6

=> s l12 and l6

L14	1	L12 AND L6

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 1 USPATFULL on STN
TI Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
AB Disclosed are novel methods of using elongation factor p (**efp**) and related constituents of ribosomal complexes which comprise **efp**, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:26250 USPATFULL
TITLE:	Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
INVENTOR(S):	Marotti, Keith R., Kalamazoo, MI, United States Poorman, Roger A., Kalamazoo, MI, United States Wells, Peter A., Kalamazoo, MI, United States Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S):	Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-322732, filed on 28 May 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Cochrane Carlson, Karen
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	O'Connor, P.C., Cozen
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
ENTERED AT 16:56:04 ON 07 JUN 2004

L1	1	S	EFP () BINDING
L2	679	S	EFP
L3	112	S	L2 AND BINDING
L4	0	S	L3 AND INCREASE BINDING
L5	58	S	L3 AND INCREASE
L6	44	S	L5 AND COMPOUND

```
L7             8 S "L16 PROTEIN"
L8             0 S PUTATIVE EFP
L9             0 S PUTATIVE EFP?
L10           16 S OXAXOLIDINONE
L11          179 S EPEREZOLID
L12         2222 S LINEZOLID
L13            1 S L11 AND L6
L14            1 S L12 AND L6

=> s l6 and l10
L15            0 L6 AND L10

=> d l10 ti abs ibib tot

L10  ANSWER 1 OF 16  USPATFULL on STN
TI     Methods and compounds for inhibiting beta-amyloid peptide release and/or
       its synthesis
AB     Disclosed are compounds which inhibit β-amyloid peptide release
       and/or its synthesis, and, accordingly, have utility in treating
       Alzheimer's disease. Also disclosed pharmaceutical compositions
       comprising a compound which inhibits β-amyloid peptide release
       and/or its synthesis as well as methods for treating Alzheimer's disease
       both prophylactically and therapeutically with such pharmaceutical
       compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2003:325042  USPATFULL
TITLE:                   Methods and compounds for inhibiting beta-amyloid
                         peptide release and/or its synthesis
INVENTOR(S):             Audia, James E., Indianapolis, IN, UNITED STATES
                         Britton, Thomas C., Carmel, IN, UNITED STATES
                         Droste, James J., Indianapolis, IN, UNITED STATES
                         Folmer, Beverly K., Newark, DE, UNITED STATES
                         Huffman, George W., Carmel, IN, UNITED STATES
                         John, Varghese, San Francisco, CA, UNITED STATES
                         Latimer, Lee H., Oakland, CA, UNITED STATES
                         Mabry, Thomas E., Indianapolis, IN, UNITED STATES
                         Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
                         Porter, Warren J., Indianapolis, IN, UNITED STATES
                         Reel, Jon K., Carmel, IN, UNITED STATES
                         Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
                         Tung, Jay S., Belmont, CA, UNITED STATES
                         Wu, Jing, San Mateo, CA, UNITED STATES
                         Eid, Clark Norman, Cheshire, CT, UNITED STATES
                         Scott, William Leonard, Indianapolis, IN, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003229024      A1   20031211
APPLICATION INFO.:       US 2002-309569     A1   20021203  (10)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 2001-789487, filed on 20
                         Feb 2001, PENDING Continuation of Ser. No. US
                         1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US
                         6191166

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 1996-108166P    19961122 (60)
                         US 1997-64859P     19970228 (60)
                         US 1997-108161P    19970228 (60)
                         US 1997-98558P     19970228 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404,
```

Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
LINE COUNT: 14968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 16 USPATFULL on STN
TI Models and methods of integrating simulation techniques for advanced material predictive analysis
AB A method of designing an electronic component comprises: a) modeling a first material with respect to a characteristic of the first material in a sufficient detail to at least partially account for a first value for the characteristic; b) modeling a second material with respect to a characteristic of the second material in a sufficient detail to at least partially account for a second value for the characteristic; c) modeling an interface between the first material and the second material such that in at least some instances the characteristic of the interface does not have an obvious characteristic or obvious value of between the first value and the second value; and d) generating a set of evaluation data from the modeling of the interface. A modeling system is also disclosed comprising: a) a computer; b) an output device operatively coupled to the computer that outputs a set of evaluation data; c) a plurality of sets of controls coupled to the computer; and d) a software code that models a first material with respect to a characteristic of the first material in a sufficient detail to at least partially account for a first value for the characteristic; models a second material with respect to a characteristic of the second material in a sufficient detail to at least partially account for a second value for the characteristic; models an interface between the first material and the second material such that in at least some instances the characteristic of the interface does not have a value of between the first value and the second value; and generates the set of evaluation data from the modeling of the interface, wherein the code is run by the computer and is coupled to the controls and to the video display.

ACCESSION NUMBER: 2003:237538 USPATFULL
TITLE: Models and methods of integrating simulation techniques for advanced material predictive analysis
INVENTOR(S): Iwamoto, Nancy, Ramona, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003165695	A1	20030904
APPLICATION INFO.:	US 2002-326233	A1	20021219 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-726066, filed on 29 Nov 2000, GRANTED, Pat. No. US 6544650 Continuation-in-part of Ser. No. US 2000-543628, filed on 5 Apr 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Sandra P. Thompson, Riordan & McKinzie, Plaza Tower, 600 Anton Blvd., 18th Floor, Costa Mesa, CA, 92626-1924
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 1187

L10 ANSWER 3 OF 16 USPATFULL on STN
TI Compositions and methods relating to novel benzodiazepine compounds and targets thereof
AB The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of

conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:173185 USPATFULL
TITLE:	Compositions and methods relating to novel benzodiazepine compounds and targets thereof
INVENTOR(S):	Glick, Gary D., Ann Arbor, MI, UNITED STATES Opipari, Anthony W., Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S):	Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119029	A1	20030626
APPLICATION INFO.:	US 2002-217878	A1	20020813 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-767283, filed on 22 Jan 2001, PENDING Continuation of Ser. No. US 2000-700101, filed on 8 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-US11599, filed on 27 Apr 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131761P	19990430 (60)
	US 1999-165511P	19991115 (60)
	US 2000-191855P	20000324 (60)
	US 2001-312560P	20010815 (60)
	US 2001-313689P	20010820 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, 101 Howard Street, Suite 350, San Francisco, CA, 94105
NUMBER OF CLAIMS:	53
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	14 Drawing Page(s)
LINE COUNT:	3901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 16 USPATFULL on STN

TI Method for producing 5-aryloxymethyl-2-oxazolidinones

AB The present invention provides a method for making 5-aryloxymethyl-2-oxazolidinone and derivatives thereof having the general formula of: ##STR1##

wherein R.sub.1 and R.sub.2 are hydrogen, alkyl, or alkoxyl group and wherein the alkyl or alkoxyl group contains no more than three carbon atoms in straight or branched chain. The invention involves the fusion of a triglycidyl isocyanurate (TGIC) with an unsubstituted or a mono- or di-substituted phenol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:130023 USPATFULL
TITLE:	Method for producing 5-aryloxymethyl-2-oxazolidinones
INVENTOR(S):	Lee, Fang-Yu, Taichung, TAIWAN, PROVINCE OF CHINA Huang, Tsang-miao, Chunghua, TAIWAN, PROVINCE OF CHINA Chung, Chao-Ho, Hsinchu, TAIWAN, PROVINCE OF CHINA
PATENT ASSIGNEE(S):	Yung Shin Pharma Ind. Co., Ltd., Taichung, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562980	B1	20030513

APPLICATION INFO.: US 2002-222797 20020819 (10)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Shiao, Rei-Tsang
LEGAL REPRESENTATIVE: Chao, Fei-Fei, Venable, Baetjer, Howard & Civiletti, LLP
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 16 USPATFULL on STN
TI Compounds for inhibiting β-amyloid peptide release and/or its synthesis
AB Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:291111 USPATFULL
TITLE: Compounds for inhibiting β-amyloid peptide release and/or its synthesis
INVENTOR(S): Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6476263	B1	20021105
APPLICATION INFO.:	US 2001-826412		20010403 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now patented, Pat. No. US 6211235
Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-108166P	19961122 (60)
	US 1997-64859P	19970228 (60)
	US 1997-108161P	19970228 (60)
	US 1997-98558P	19970228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis LLP
NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 12409
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 16 USPATFULL on STN
TI Novel polymer/substrate and polymer/polymer interfaces and methods of modeling and forming same
AB A polymer/substrate and/or polymer/polymer interface is selected from candidate interfaces using a model that manipulates adhesive characteristics and strain variables, and estimates of their effect on candidate interfaces. The model is preferably used to evaluate properties such as size, shape, and bond geometries. Preferred models involve an atomic level visual representation of a first polymer adhered to either a second polymer or a substrate at the interface by a force, inclusion of strain-related information, and generating data from modeling effects on the interface of strain cycles resulting from intermittently applied force. Particularly preferred interfaces include a polymer having a monomer of the formula: ##STR1##

wherein R.sub.a, R.sub.b, R.sub.c comprises a hydroxylated aliphatic side chain; an epoxy glycol; an ethoxy ether; a glycol ether; an adduct of glycol ether and a bisphenol glycol epoxy; an adduct of an epoxy glycol and an amine such as oxydianiline to form a hydroxylamine; an adduct of a glycol ether and a cycloaliphatic epoxy such as oxybiscyclopentene oxide; an adduct of hydroxyethyl side chain and a cycloaliphatic epoxy such as oxybiscylopentene.

ACCESSION NUMBER: 2002:284965 USPATFULL
TITLE: Novel polymer/substrate and polymer/polymer interfaces and methods of modeling and forming same
INVENTOR(S): Iwamoto, Nancy E., Ramona, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002157788	A1	20021031
APPLICATION INFO.:	US 2002-113461	A1	20020328 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-543628, filed on 5 Apr 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rutan & Tucker, LLP, 14th Floor, 611 Anton Blvd., Costa Mesa, CA, 92626
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 992

L10 ANSWER 7 OF 16 USPATFULL on STN
TI Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AB Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:99421 USPATFULL
TITLE: Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
INVENTOR(S): Audia, James E., Indianapolis, IN, UNITED STATES

Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052322	A1	20020502
APPLICATION INFO.:	US 2001-789487	A1	20010220 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US 6191166

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-108166P	19961122 (60)
	US 1997-108161P	19970228 (60)
	US 1997-98558P	19970228 (60)
	US 1997-64859P	19970228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
LINE COUNT: 14911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 16 USPATFULL on STN
TI Models and methods of integrating simulation techniques for advanced material predictive analysis
AB A method of designing an electronic component comprises: a) modeling a first material with respect to a characteristic of the first material in a sufficient detail to at least partially account for a first value for the characteristic; b) modeling a second material with respect to a characteristic of the second material in a sufficient detail to at least partially account for a second value for the characteristic; c) modeling an interface between the first material and the second material such that in at least some instances the characteristic of the interface does not have an obvious characteristic or obvious value of between the first value and the second value; and d) generating a set of evaluation data from the modeling of the interface. A modeling system is also disclosed comprising: a) a computer; b) an output device operatively coupled to the computer that outputs a set of evaluation data; c) a plurality of sets of controls coupled to the computer; and d) a software code that models a first material with respect to a characteristic of the first material in a sufficient detail to at least partially account for a first value for the characteristic; models a second material with respect to a characteristic of the second material in a sufficient detail to at least partially account for a second value for the characteristic; models an interface between the first material and the second material such that in at least some instances the characteristic of the interface does not have a value of between the first value and the second value; and generates the set of evaluation data from the

modeling of the interface, wherein the code is run by the computer and is coupled to the controls and to the video display.

ACCESSION NUMBER: 2002:61609 USPATFULL
TITLE: Models and methods of integrating simulation techniques for advanced material predictive analysis
INVENTOR(S): Iwamoto, Nancy E., Ramona, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002035446	A1	20020321
	US 6544650	B2	20030408
APPLICATION INFO.:	US 2000-726066	A1	20001129 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-543628, filed on 5 Apr 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Honeywell International Inc., Attention: Patent Services AB2B, 101 Columbia Road, Morristown, NJ, 07962-2245
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 1183

L10 ANSWER 9 OF 16 USPATFULL on STN
TI Treatment of urinary tract infections with antibacterial oxazolidinones
AB The present invention is a method of treating a warm blooded mammal who has a urinary tract infection caused by a Gram-positive organism who is in need of such treatment, which comprises administering to the mammal in need of such treatment a urinary therapeutically effective amount of an antibacterial oxazolidinone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:218502 USPATFULL
TITLE: Treatment of urinary tract infections with antibacterial oxazolidinones
INVENTOR(S): Batts, Donald Herman, Kalamazoo, MI, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001046992	A1	20011129
APPLICATION INFO.:	US 2001-809447	A1	20010315 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190961P	20000322 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Bruce Stein, Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI, 49001
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 16 USPATFULL on STN
TI Therapeutic application of pro-apoptotic benzodiazepines
AB Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of the following structures: ##STR1##

wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drug screening assays and other diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:139541 USPATFULL
TITLE:	Therapeutic application of pro-apoptotic benzodiazepines
INVENTOR(S):	Glick, Gary D., Ann Arbor, MI, United States Opipari, Anthony W., JR., Ann Arbor, MI, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016583	A1	20010823
APPLICATION INFO.:	US 2001-767283	A1	20010122 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-700101, filed on 8 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-US11599, filed on 27 Apr 2000, UNKNOWN Continuation-in-part of Ser. No. US 1997-881037, filed on 23 Jun 1997, GRANTED, Pat. No. US 6080588 Division of Ser. No. US 1995-443540, filed on 18 May 1995, ABANDONED Continuation-in-part of Ser. No. US 1998-18026, filed on 2 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-943983, filed on 3 Oct 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131761P	19990430 (60)
	US 1999-165511P	19991115 (60)
	US 1999-165855P	19991116 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Atoinette F. Konski, Baker & McKenzie, 660 Hansen Way, Palo Alto, CA, 94304
NUMBER OF CLAIMS:	129
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Page(s)
LINE COUNT:	2737

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 16 USPATFULL on STN

TI Compounds for inhibiting β-amyloid peptide release and/or its synthesis

AB Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:48108 USPATFULL
TITLE:	Compounds for inhibiting β-amyloid peptide release and/or its synthesis
INVENTOR(S):	Wu, Jing, San Mateo, CA, United States Tung, Jay S., Belmont, CA, United States Thorsett, Eugene D., Moss Beach, CA, United States

Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211235	B1	20010403
APPLICATION INFO.:	US 1998-164448		19980930 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-108166P	19961122 (60)
	US 1997-64859P	19970228 (60)
	US 1997-98558P	19970228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 14056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 16 USPATFULL on STN
TI Compounds for inhibiting β-amyloid peptide release and/or its synthesis
AB Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:44268 USPATFULL
TITLE: Compounds for inhibiting β-amyloid peptide release and/or its synthesis
INVENTOR(S): Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., South San Francisco, CA,

United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207710	B1	20010327
APPLICATION INFO.:	US 1998-164385		19980930 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-108166P	19961122 (60)
	US 1997-64859P	19970228 (60)
	US 1997-108161P	19970228 (60)
	US 1997-98558P	19970228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 12026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 16 USPATFULL on STN
TI Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
AB Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:25931 USPATFULL
TITLE: Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
INVENTOR(S): Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
Varghese, John, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
Eid, Clark Norman, Cheshire, CT, United States
Scott, William Leonard, Indianapolis, IN, United States
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6191166 B1 20010220
APPLICATION INFO.: US 1997-976289 19971121 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-108166P	19961122 (60)
	US 1997-64859P	19970228 (60)
	US 1997-108161P	19970228 (60)
	US 1997-698556P	19970228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Killos, Paul J.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 12827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 16 USPATFULL on STN
TI Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof
AB A process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines is described where N-protected DL-3,3-diphenylalanine or N-protected-DL-substituted 3,3-diphenylalanine are treated with (-)cinchonidine and the resulting salt resolved into the desired enantiomers, as well as derivatives thereof and valuable intermediates used in the process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 93:25024 USPATFULL
TITLE: Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof
INVENTOR(S): Beylin, Vladimir, Ann Arbor, MI, United States
Chen, Huai G., Ann Arbor, MI, United States
Goel, Om P., Ann Arbor, MI, United States
Topliss, John G., Ann Arbor, MI, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5198548		19930330
APPLICATION INFO.:	US 1992-828399		19920130 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Clarke, Vera C.
LEGAL REPRESENTATIVE: Tinney, Francis J.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 8
LINE COUNT: 774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 16 USPATFULL on STN
TI Pyrimidine derivative
AB The present invention relates to a pyrimidine derivative having the formula ##STR1## (wherein the variables are defined in the full text of the patent), a method for producing the same, and its use as a herbicide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 92:63488 USPATFULL
TITLE: Pyrimidine derivative

INVENTOR(S):	Hiratsuka, Mitsunori, Toyonaka, Japan Hirata, Naonori, Sanda, Japan Saitoh, Kazuo, Toyonaka, Japan Shibata, Hideyuki, Toyonaka, Japan
PATENT ASSIGNEE(S):	Sumitomo Chemical Company, Limited, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5135563		19920804	
APPLICATION INFO.:	US 1991-726218		19910705	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-178967	19900705
	JP 1991-124816	19910426

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Ford, John M.
LEGAL REPRESENTATIVE:	Stevens, Davis, Miller & Mosher
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	12
LINE COUNT:	2104

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 16 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Once-a-day antibiotic product useful for treating bacterial infection comprises first, second, and third dosage forms, each having at least one antibiotic and carrier.

AN 2003-876815 [81] WPIDS

CR 2001-602490 [68]

AB WO2003075852 A UPAB: 20040514

NOVELTY - Once-a-day antibiotic product comprises first, second, and third dosage forms. Each having at least one antibiotic and a carrier. One of the dosage forms comprises a first antibiotic and a second antibiotic different from the first antibiotic. The third dosage form comprises at least one of the first and second antibiotics. The first dosage form is an immediate release dosage form and the second and third forms are delayed release dosage forms.

DETAILED DESCRIPTION - A once-a-day antibiotic product comprises first, second, and third dosage forms. Each dosage forms comprises at least one antibiotic and a carrier. One of the dosage forms comprises at least a first antibiotic selected from tetracycline, ciprofoxacin, amoxicillin, and cephalosporin; and at least one of the dosage forms comprises at least a second antibiotic that is different from the first antibiotic such that: when the first antibiotic is tetracycline, the second antibiotic is doxycycline; when the first antibiotic is ciprofoxacin the second antibiotic is metronidazole; when the first antibiotic is amoxicillin, the second antibiotic is either clarithromycin or dicloxacillin; and when the first antibiotic is cephalosporin the second antibiotic is metronidazole. The third dosage form comprises at least one of the first and second antibiotics. The first dosage form is an immediate release dosage form; the second and third dosage forms are delayed release dosage forms.

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - None given.

USE - For treating a bacterial infection in host (claimed).

ADVANTAGE - Each of the first, second, and third dosage forms initiate release of antibiotic at different times and Cmax in serum of the total antibiotic released from the antibiotic product is achieved in less than about 12 hours from administration; and the once-a-day antibiotic product contains the total dosage of at least two different antibiotics for a twenty-four hour period. The antibiotic released from the second dosage form reaches a Cmax in serum after antibiotic released from the

first dosage reaches a Cmax in serum. The antibiotic released form the third dosage form reaches a Cmax in serum after antibiotic released from the second dosage form reaches Cmax in serum. The antibiotic released from the second dosage form reaches a Cmax in serum in not more than 4 hours after administration of the product. The antibiotic released from the second and third dosage form reaches a Cmax in serum within 8 hours after administration of the product. The first antibiotic released from second dosage form and the second antibiotic released from the third dosage form reach a Cmax in serum at about same time.

Dwg.0/0

ACCESSION NUMBER: 2003-876815 [81] WPIDS
CROSS REFERENCE: 2001-602490 [68]
DOC. NO. CPI: C2003-247390
TITLE: Once-a-day antibiotic product useful for treating bacterial infection comprises first, second, and third dosage forms, each having at least one antibiotic and carrier.
DERWENT CLASS: B05 B07
INVENTOR(S): ISBITER, J D; RUDNIC, E M; TREACY, D J; WASSINK, S E; ISBISTER, J D
PATENT ASSIGNEE(S): (ADPH-N) ADVANCED PHARMA INC
COUNTRY COUNT: 103
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003075852	A2	20030918	(200381)*	EN	98
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 6627222	B2	20030930	(200381)		
US 6632453	B2	20031014	(200381)		
US 6638532	B2	20031028	(200381)		
AU 2003218024	A1	20030922	(200431)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2003075852	A2		WO 2003-US7118	20030307
US 6627222	B2	Provisional	US 2000-184545P	20000224
		CIP of	US 2001-791983	20010223
			US 2002-92854	20020307
US 6632453	B2	Provisional	US 2000-184545P	20000224
		CIP of	US 2001-791983	20010223
			US 2002-92858	20020307
US 6638532	B2	Provisional	US 2000-184545P	20000224
		CIP of	US 2001-791983	20010223
			US 2002-93214	20020307
AU 2003218024	A1		AU 2003-218024	20030307

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2003218024	A1	Based on	WO 2003075852

PRIORITY APPLN. INFO: US 2002-93321 20020307; US
2002-92811 20020307; US
2002-92854 20020307; US

```
                    2002-92858        20020307; US
                    2002-93214        20020307; US
                    2000-184545P      20000224; US
                    2001-791983       20010223


=> d his

     (FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
     ENTERED AT 16:56:04 ON 07 JUN 2004
L1             1 S EFP () BINDING
L2           679 S EFP
L3           112 S L2 AND BINDING
L4             0 S L3 AND INCREASE BINDING
L5            58 S L3 AND INCREASE
L6            44 S L5 AND COMPOUND
L7             8 S "L16 PROTEIN"
L8             0 S PUTATIVE EFP
L9             0 S PUTATIVE EFP?
L10           16 S OXAXOLIDINONE
L11          179 S EPEREZOLID
L12         2222 S LINEZOLID
L13            1 S L11 AND L6
L14            1 S L12 AND L6
L15            0 S L6 AND L10

=> s l2 and l11
L16            2 L2 AND L11

=> d l16 ti abs ibib tot

L16  ANSWER 1 OF 2  USPATFULL on STN
TI     Elongation factor P (EFP) and assays and antimicrobial
       treatments related to the same
AB     Disclosed are novel methods of using elongation factor p (efp)
       and related constituents of ribosomal complexes which comprise
       efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the
       70S initiation complex, and related proteins, cofactors and enzymes.
       Methods of identifying compounds which modulate prokaryotic elongation
       factor p and modify cell function are described. Both in vitro and in
       vivo methods for identifying compounds which modulate such constituents
       and affect cell function are described. Such identified compounds,
       including various antibiotics, which specifically affect cell growth,
       methods of treating various disorders with such compounds, and
       antiseptics containing such compounds are described. The present
       invention is also directed to methods and compounds that modulate
       prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:26250  USPATFULL
TITLE:                  Elongation factor P (EFP) and assays and
                        antimicrobial treatments related to the same
INVENTOR(S):            Marotti, Keith R., Kalamazoo, MI, United States
                        Poorman, Roger A., Kalamazoo, MI, United States
                        Wells, Peter A., Kalamazoo, MI, United States
                        Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S):     Pharmacia & Upjohn Company, Kalamazoo, MI, United
                        States (U.S. corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 6511813          B1   20030128
```

APPLICATION INFO.: US 2000-704321 20001102 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-322732, filed on 28 May 1999

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Cochrane Carlson, Karen
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: O'Connor, P.C., Cozen
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 2 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.
AN 2000-524303 [47] WPIDS
AB WO 200045177 A UPAB: 20000925
NOVELTY - A method (M1) for identifying a compound which modulates the activity of **efp** comprises contacting **efp** with a compound and determining whether the compound modifies activity of **efp**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell containing **efp** with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a composition comprising **efp**, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of **efp**, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to **efp** in association with the 30S subunit or 70S ribosome or interferes with the binding of **efp** and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell or composition containing **efp** with a detectably labelled oxazolidinone compound known to bind **efp**;

(b) contacting the composition or cell with an unlabelled compound; and

(c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates **efp** but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic **efp** by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp** , the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS
DOC. NO. NON-CPI: N2000-387540
DOC. NO. CPI: C2000-155724
TITLE: Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN; (PHAA) PHARMACIA & UPJOHN CO
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		
EP 1147422	A1	20011024	(200171)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002535680	W	20021022	(200301)		63
US 6511813	B1	20030128	(200311)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

```
     EP 1147422      A1                EP 1999-926086       19990528
                                       WO 1999-US12073      19990528
     JP 2002535680   W                 WO 1999-US12073      19990528
                                       JP 2000-596378       19990528
     US 6511813      B1 Provisional    US 1999-117473P      19990127
                        Div ex         US 1999-322732       19990528
                                       US 2000-704321       20001102

FILING DETAILS:

     PATENT NO       KIND                PATENT NO
     ------------------------------------------------
     AU 9942246      A  Based on         WO 2000045177
     EP 1147422      A1 Based on         WO 2000045177
     JP 2002535680   W  Based on         WO 2000045177

PRIORITY APPLN. INFO: US 1999-117473P      19990127; US
                      1999-322732       19990528; US
                      2000-704321       20001102


=> d his

     (FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
     ENTERED AT 16:56:04 ON 07 JUN 2004
L1             1 S EFP () BINDING
L2           679 S EFP
L3           112 S L2 AND BINDING
L4             0 S L3 AND INCREASE BINDING
L5            58 S L3 AND INCREASE
L6            44 S L5 AND COMPOUND
L7             8 S "L16 PROTEIN"
L8             0 S PUTATIVE EFP
L9             0 S PUTATIVE EFP?
L10           16 S OXAXOLIDINONE
L11          179 S EPEREZOLID
L12         2222 S LINEZOLID
L13            1 S L11 AND L6
L14            1 S L12 AND L6
L15            0 S L6 AND L10
L16            2 S L2 AND L11

=> s l12 and l2
L17            2 L12 AND L2

=> d l17 ti abs ibib tot

L17  ANSWER 1 OF 2  USPATFULL on STN
TI     Elongation factor P (EFP) and assays and antimicrobial
       treatments related to the same
AB     Disclosed are novel methods of using elongation factor p (efp)
       and related constituents of ribosomal complexes which comprise
       efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the
       70S initiation complex, and related proteins, cofactors and enzymes.
       Methods of identifying compounds which modulate prokaryotic elongation
       factor p and modify cell function are described. Both in vitro and in
       vivo methods for identifying compounds which modulate such constituents
       and affect cell function are described. Such identified compounds,
       including various antibiotics, which specifically affect cell growth,
       methods of treating various disorders with such compounds, and
       antiseptics containing such compounds are described. The present
       invention is also directed to methods and compounds that modulate
```

prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:26250 USPATFULL
TITLE:	Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
INVENTOR(S):	Marotti, Keith R., Kalamazoo, MI, United States Poorman, Roger A., Kalamazoo, MI, United States Wells, Peter A., Kalamazoo, MI, United States Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S):	Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-322732, filed on 28 May 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Cochrane Carlson, Karen
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	O'Connor, P.C., Cozen
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1234

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 2 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.

AN 2000-524303 [47] WPIDS

AB WO 200045177 A UPAB: 20000925

NOVELTY - A method (M1) for identifying a compound which modulates the activity of **efp** comprises contacting **efp** with a compound and determining whether the compound modifies activity of **efp**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell containing **efp** with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a composition comprising **efp**, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of **efp**, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and
(c) determining whether the compound binds to **efp** in association with the 30S subunit or 70S ribosome or interferes with the binding of **efp** and the 30S subunit or 70S ribosome;
(4) a method (M5) for identifying a compound which modulates **efp** activity comprising:
(a) contacting **efp** with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;
(b) contacting the second composition with the compound; and
(c) determining whether the compound inhibits the first peptide bond reaction;
(5) a method (M6) for identifying a compound which modulates **efp** activity comprising:
(a) contacting a cell or composition containing **efp** with a detectably labelled oxazolidinone compound known to bind **efp**;
(b) contacting the composition or cell with an unlabelled compound; and
(c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;
(6) a method (M7) for identifying a compound which modulates **efp** but not eukaryotic eIF5A activity comprising:
(a) determining whether the compound modulates the activity of prokaryotic **efp** by M1 - M7;
(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;
(c) contacting the second composition with a compound; and
(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and
(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp** , the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.
USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.
ADVANTAGE - This screening method is more rapid and direct than currently available methods.
Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS
DOC. NO. NON-CPI: N2000-387540
DOC. NO. CPI: C2000-155724
TITLE: Identifying a compound which modulates the activity of prokaryotic elongation factor p (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN; (PHAA) PHARMACIA & UPJOHN CO
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB

```
          GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
          LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
          TT UA UG US UZ VN YU ZA ZW
     AU 9942246      A  20000818 (200057)
     EP 1147422      A1 20011024 (200171)  EN
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
          RO SE SI
     JP 2002535680   W  20021022 (200301)       63
     US 6511813      B1 20030128 (200311)

APPLICATION DETAILS:

     PATENT NO      KIND                    APPLICATION         DATE
     ---------------------------------------------------------------
     WO 2000045177  A1                     WO 1999-US12073     19990528
     AU 9942246     A                      AU 1999-42246       19990528
     EP 1147422     A1                     EP 1999-926086      19990528
                                           WO 1999-US12073     19990528
     JP 2002535680  W                      WO 1999-US12073     19990528
                                           JP 2000-596378      19990528
     US 6511813     B1 Provisional         US 1999-117473P     19990127
                       Div ex              US 1999-322732      19990528
                                           US 2000-704321      20001102

FILING DETAILS:

     PATENT NO       KIND                   PATENT NO
     ------------------------------------------------
     AU 9942246      A  Based on            WO 2000045177
     EP 1147422      A1 Based on            WO 2000045177
     JP 2002535680   W  Based on            WO 2000045177

PRIORITY APPLN. INFO: US 1999-117473P      19990127; US
                      1999-322732       19990528; US
                      2000-704321       20001102


=> d his

     (FILE 'HOME' ENTERED AT 16:54:36 ON 07 JUN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS'
     ENTERED AT 16:56:04 ON 07 JUN 2004
L1             1 S EFP () BINDING
L2           679 S EFP
L3           112 S L2 AND BINDING
L4             0 S L3 AND INCREASE BINDING
L5            58 S L3 AND INCREASE
L6            44 S L5 AND COMPOUND
L7             8 S "L16 PROTEIN"
L8             0 S PUTATIVE EFP
L9             0 S PUTATIVE EFP?
L10           16 S OXAXOLIDINONE
L11          179 S EPEREZOLID
L12         2222 S LINEZOLID
L13            1 S L11 AND L6
L14            1 S L12 AND L6
L15            0 S L6 AND L10
L16            2 S L2 AND L11
L17            2 S L12 AND L2

=> s l10 and l2
L18            0 L10 AND L2
```

```
=> Marotti, k/au
MAROTTI, IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> e marotti, k/au
E1            2     MAROTTI VINCENT/AU
E2            1     MAROTTI VINCENT A/AU
E3            0 --> MAROTTI, K/AU
E4            7     MAROTTO A/AU
E5            4     MAROTTO A F/AU
E6            1     MAROTTO ALAN P/AU
E7            2     MAROTTO ANNALISA/AU
E8            5     MAROTTO ANTHONY F/AU
E9            1     MAROTTO D R/AU
E10           1     MAROTTO F/AU
E11           1     MAROTTO F R/AU
E12           1     MAROTTO L/AU

=> s efp and increase fluorescence
L19           0 EFP AND INCREASE FLUORESCENCE

=> s efp  and  (fluorescence)
L20          42 EFP AND (FLUORESCENCE)

=> s l20 and (increase)
L21          32 L20 AND (INCREASE)

=> s l21 and (binding)
L22          31 L21 AND (BINDING)

=> d l22 ti abs ibib tot

L22  ANSWER 1 OF 31  USPATFULL on STN
TI     Methods and systems for assessing biological materials using optical and
       spectroscopic detection techniques
AB     Optical detection techniques for the assessment of the physiological
       state, health and/or viability of biological materials are provided.
       Biological materials which may be examined using such techniques include
       cells, tissues, organs, subcellular components and intact animals. The
       inventive techniques may be employed in screening of potential
       diagnostic and/or therapeutic agents. One or more maps of data that
       correspond to the optical properties of a sample may be created and
       viewed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2004:69503  USPATFULL
TITLE:                   Methods and systems for assessing biological materials
                         using optical and spectroscopic detection techniques
INVENTOR(S):             Hochman, Daryl W., Bahama, NC, UNITED STATES
PATENT ASSIGNEE(S):      CYTOSCAN SCIENCES, L.L.C., Seattle, WA (U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004052730      A1   20040318
APPLICATION INFO.:       US 2003-454153     A1   20030603  (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2001-1366, filed on
                         30 Oct 2001, GRANTED, Pat. No. US 6573063
                         Continuation-in-part of Ser. No. US 2000-629046, filed
                         on 31 Jul 2000, GRANTED, Pat. No. US 6319682
                         Continuation-in-part of Ser. No. US 1999-326008, filed
                         on 4 Jun 1999, GRANTED, Pat. No. US 6096510
```

Continuation-in-part of Ser. No. US 1997-949416, filed on 14 Oct 1997, GRANTED, Pat. No. US 5976825
Continuation-in-part of Ser. No. US 1995-539296, filed on 4 Oct 1995, GRANTED, Pat. No. US 5902732
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SPECKMAN LAW GROUP, 1501 WESTERN AVE, SUITE 100, SEATTLE, WA, 98101
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 31 USPATFULL on STN
TI DNA array sequence selection
AB The present invention provides methods and compositions for the construction of custom cDNA microarrays. In particular, the methods involve the selection of relevant clusters based on knowledge and expression patterns using public database information and the identification of the best representative cDNA clones within the selected cluster. The methods facilitate the construction of custom microarrays suitable for use in any biotechnological art. In preferred embodiments, the present invention provides the the ImmunoChip.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:66006 USPATFULL
TITLE: DNA array sequence selection
INVENTOR(S): Lorenz, Matthias, Bethesda, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6706867	B1	20040316	
APPLICATION INFO.:	US 2000-741238		20001219	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Horlick, Kenneth R.
ASSISTANT EXAMINER: Wilder, Cynthia
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 23532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 31 USPATFULL on STN
TI Circularly permuted fluorescent protein indicators
AB The present invention provides polypeptide and polynucleotides encoding fluorescent indicators having inserted within a fluorescent moiety a sensor polypeptide. Also provided are methods of using the fluorescent indicator. Circularly permuted fluorescent polypeptides and polynucleotides are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:53306 USPATFULL
TITLE: Circularly permuted fluorescent protein indicators
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, United States
Baird, Geoffrey, Solana Beach, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699687	B1	20040302
APPLICATION INFO.:	US 1999-316920		19990521 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Murphy, Joseph F.
LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 31 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same
AB The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:39248 USPATFULL
TITLE: Novel proteins and nucleic acids encoding same
INVENTOR(S): Anderson, David W., Branford, CT, UNITED STATES
Berghs, Constance, New Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Catterton, Elina, Madison, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Jeffers, Michael E., Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES

Zhong, Mei, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029789	A1	20040212
APPLICATION INFO.:	US 2002-188186	A1	20020702 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303046P	20010705 (60)
	US 2002-360814P	20020301 (60)
	US 2001-303828P	20010709 (60)
	US 2001-323380P	20010919 (60)
	US 2002-361133P	20020301 (60)
	US 2001-304016P	20010709 (60)
	US 2001-304502P	20010711 (60)
	US 2001-305262P	20010713 (60)
	US 2002-373881P	20020419 (60)
	US 2001-305673P	20010716 (60)
	US 2001-323969P	20010921 (60)
	US 2002-372326P	20020412 (60)
	US 2002-361677P	20020305 (60)
	US 2002-345022P	20020104 (60)
	US 2002-363637P	20020312 (60)
	US 2002-373921P	20020419 (60)
	US 2001-307536P	20010724 (60)
	US 2002-360830P	20020301 (60)
	US 2001-306085P	20010717 (60)
	US 2001-308228P	20010727 (60)
	US 2002-372990P	20020416 (60)
	US 2002-361147P	20020301 (60)
	US 2001-308877P	20010730 (60)
	US 2002-345038P	20020104 (60)
	US 2002-361172P	20020228 (60)
	US 2001-313328P	20010817 (60)
	US 2001-318711P	20010912 (60)
	US 2001-309255P	20010801 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 23357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 31 USPATFULL on STN
TI Nucleotide sequence of the haemophilus influenza Rd genome, fragments thereof, and uses thereof
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique NotI restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:24664 USPATFULL
TITLE: Nucleotide sequence of the haemophilus influenza Rd genome, fragments thereof, and uses thereof
INVENTOR(S): Fleischmannn, Robert D., Gaithersburg, MD, UNITED

STATES
Adams, Mark D., Rockville, MD, UNITED STATES
White, Owen, Rockville, MD, UNITED STATES
Smith, Hamilton O., Reisterstown, MD, UNITED STATES
Venter, J. Craig, Queenstown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018503	A1	20040129
APPLICATION INFO.:	US 2002-329670	A1	20021227 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-643990, filed on 23 Aug 2000, GRANTED, Pat. No. US 6528289 Continuation of Ser. No. US 1995-487429, filed on 7 Jun 1995, GRANTED, Pat. No. US 6468765 Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 47 Drawing Page(s)
LINE COUNT: 5593
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 31 USPATFULL on STN
TI Fluorescent protein sensors for measuring the pH of a biological sample
AB Disclosed are fluorescent protein sensors for measuring the pH of a sample, nucleic acids encoding them, and methods of use. The preferred fluorescent protein sensors are variants of the green fluorescent protein (GFP) from Aequora victoria. Also disclosed are compositions and methods for measuring the pH of a specific region of a cell, such as the mitochondrial matrix or the Golgi lumen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:301039 USPATFULL
TITLE: Fluorescent protein sensors for measuring the pH of a biological sample
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, UNITED STATES
Llopis, Juan, San Diego, CA, UNITED STATES
Wachter, Rebekka M., Creswell, OR, UNITED STATES
Remington, S. James, Eugene, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003212265	A1	20031113
APPLICATION INFO.:	US 2003-457982	A1	20030609 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-602641, filed on 22 Jun 2000, GRANTED, Pat. No. US 6608189 Continuation-in-part of Ser. No. US 1998-94359, filed on 9 Jun 1998, GRANTED, Pat. No. US 6140132
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3086
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 7 OF 31 USPATFULL on STN

TI Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

AB The present ivention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:276367 USPATFULL

TITLE: Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

INVENTOR(S): Charneau, Pierre, Paris, FRANCE
Zennou, Veronique, Paris, FRANCE
Pflumio, Francoise, Vitry Sur Seine, FRANCE
Sirven, Aude, Paris, FRANCE
Dubart Kupperschmitt, Anne, Choisy Le Roi, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003194392	A1	20031016	
APPLICATION INFO.:	US 2002-122114	A1	20020410	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 2073

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 8 OF 31 USPATFULL on STN

TI Nucleotide sequence of the Mycoplasma genitalium genome, fragments thereof, and uses thereof

AB The present invention provides the nucleotide sequence of the entire genome of Mycoplasma genitalium, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies protein encoding fragments of the genome, and identifies, by position relative to two (2) genes known to flank the origin of replication, any regulatory elements which modulate the expression of the protein encoding fragments of the Mycoplasma genitalium genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244254 USPATFULL

TITLE: Nucleotide sequence of the Mycoplasma genitalium genome, fragments thereof, and uses thereof

INVENTOR(S): Fraser, Claire M., Potomac, MD, UNITED STATES
Adams, Mark D., Rockville, MD, UNITED STATES
Gocayne, Jeannine D., Potomac, MD, UNITED STATES
Hutchison, Clyde A., III, Chapel Hill, MD, UNITED STATES
Smith, Hamilton O., Reisterstown, MD, UNITED STATES
Venter, J. Craig, Queenstown, MD, UNITED STATES
White, Owen R., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Johns Hopkins University, Baltimore, MD (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170663	A1	20030911
APPLICATION INFO.:	US 2002-205220	A1	20020726 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-545528, filed on 19 Oct 1995, PENDING Continuation-in-part of Ser. No. US 1995-488018, filed on 7 Jun 1995, PENDING Continuation-in-part of Ser. No. US 1995-473545, filed on 7 Jun 1995, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 6270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 31 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:174195 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, UNITED STATES
Rothe, Mike, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003120043	A1	20030626
APPLICATION INFO.:	US 2002-283500	A1	20021030 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-779599, filed on 7 Jan 1997, GRANTED, Pat. No. US 6500922 Continuation of Ser. No. US 1996-744139, filed on 5 Nov 1996, GRANTED, Pat. No. US 5869612 Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, GRANTED, Pat. No. US 5708142
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 3788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 10 OF 31 USPATFULL on STN
TI Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
AB The invention provides isolated polypeptide and nucleic acid sequences derived Enterococcus faecium that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:169096 USPATFULL		
TITLE:	Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics		
INVENTOR(S):	Doucette-Stamm, Lynn A., Framingham, MA, United States Bush, David, Somerville, MA, United States		
PATENT ASSIGNEE(S):	Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6583275	B1	20030624
APPLICATION INFO.:	US 1998-107532		19980630 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-85598P		19980514 (60)
	US 1997-51571P		19970702 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Marschel, Ardin H.		
LEGAL REPRESENTATIVE:	Genome Therapeutics Corporation		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	15265		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 11 OF 31 USPATFULL on STN

TI Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics

AB The invention provides isolated polypeptide and nucleic acid sequences derived from Acinetobacter mirabilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:130010 USPATFULL		
TITLE:	Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics		
INVENTOR(S):	Breton, Gary, Marlborough, MA, United States Bush, David, Somerville, MA, United States		
PATENT ASSIGNEE(S):	Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562958	B1	20030513
APPLICATION INFO.:	US 1999-328352		19990604 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1998-88701P		19980609 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Borin, Michael		
LEGAL REPRESENTATIVE:	Genome Therapeutics Corporation		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 16618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 12 OF 31 USPATFULL on STN
TI Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
AB The present invention provides the nucleotide sequence of the entire genome of Mycoplasma genitalium, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies protein encoding fragments of the genome, and identifies, by position relative to two (2) genes known to flank the origin of replication, any regulatory elements which modulate the expression of the protein encoding fragments of the Mycoplasma genitalium genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:81597 USPATFULL
TITLE: Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
INVENTOR(S): Fraser, Claire M., Potomac, MD, United States
Adams, Mark D., N. Potomac, MD, United States
Gocayne, Jeannine D., Silver Spring, MD, United States
Hutchison, III, Clyde A., Chapel Hill, NC, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): The Institute for Genomic Research, Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6537773	B1	20030325
APPLICATION INFO.:	US 1995-545528		19951019 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-488018, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-473545, filed on 7 Jun 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Schnizer, Richard
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 15190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 13 OF 31 USPATFULL on STN
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by

position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:60089 USPATFULL
TITLE:	Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
INVENTOR(S):	Fleischmann, Robert D., Gaithersburg, MD, United States Adams, Mark D., N. Potomac, MD, United States White, Owen, Gaithersburg, MD, United States Smith, Hamilton O., Towson, MD, United States Venter, J. Craig, Potomac, MD, United States
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation) Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6528289	B1	20030304
APPLICATION INFO.:	US 2000-643990		20000823 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-487429, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Martinell, James
LEGAL REPRESENTATIVE:	Human Genome Sciences, Inc.
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT:	4428

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 14 OF 31 USPATFULL on STN

TI Microfluidic micromixer

AB A mixing apparatus is provided comprising: first driving means for driving a plurality of reagent samples from a plurality of respective source wells into a first fluid flow stream; second driving means for introducing a separation gas between each of the plurality of reagent samples in the first fluid flow stream; means for driving a second fluid flow stream comprising a plurality of particles; a junction device comprising: a first inlet port for receiving the first fluid flow stream; a second inlet port for receiving the second fluid flow stream; a reaction zone for forcing mixing between the first fluid flow stream and the second fluid flow stream to thereby form a reaction product stream; and an outlet port for allowing the reaction product stream to exit the junction device; a reaction zone where the plurality of reagent samples and the plurality of particles mix to form a plurality of reaction products, the reaction zone communicating with the outlet port; reaction product driving means for driving the reaction product stream through the reaction zone; and means for selectively analyzing the reaction product stream for the reaction products. A method for mixing materials is also provided comprising: driving a first fluid flow stream comprising a plurality of reagent samples separated by gas bubbles through a second inlet port of a junction device; driving a second fluid flow stream comprising particles through a first inlet port of the junction device; mixing the first fluid flow stream and the second fluid flow stream in a reaction zone in the junction device to form a reaction product stream; and driving the reaction product stream through an outlet port of the junction device.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:57541 USPATFULL
TITLE: Microfluidic micromixer
INVENTOR(S): Sklar, Larry A., Albuquerque, NM, UNITED STATES
Buranda, Tione, Albuquerque, NM, UNITED STATES
Edwards, Bruce S., Albuquerque, NM, UNITED STATES
Gallegos, Carlos M., Albuquerque, NM, UNITED STATES
Jackson, W. Coyt, San Diego, CA, UNITED STATES
Kuckuck, Frederick W., Albuquerque, NM, UNITED STATES
Lopez, Gabriel P., Albuquerque, NM, UNITED STATES
Mammoli, Andrea A., Albuquerque, NM, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040105	A1	20030227
APPLICATION INFO.:	US 2001-21243	A1	20011219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-501643, filed on 10 Feb 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156946P	19990930 (60)
	US 2001-330624P	20011026 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ajay A. Jagtiani, Jagtiani + Guttag, Democracy Square Business Center, 10379-B Democracy Lane, Fairfax, VA, 22030
NUMBER OF CLAIMS: 78
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 1589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 15 OF 31 USPATFULL on STN
TI Highly sensitive proteomic analysis methods, and kits and systems for practicing the same
AB Methods of determining whether a sample includes one or more analytes, particularly proteinaceous analytes, of interest are provided. In the subject methods, an array of **binding** agents, where each **binding** agent includes an epitope **binding** domain of an antibody, is contacted with the sample. In many embodiments, contact occurs in the presence of a metal ion chelating polysaccharide, e.g., a pectin. Following contact, the presence of **binding** complexes on the array surface are detected and the resultant data is employed to determine whether the sample includes the one or more analytes of interest. Also provided are kits, systems and other compositions of matter for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including proteomic applications such as protein expression analysis, e.g., differential protein expression profiling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:51138 USPATFULL
TITLE: Highly sensitive proteomic analysis methods, and kits and systems for practicing the same
INVENTOR(S): Tchaga, Grigoriy S., Newark, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003036095	A1	20030220
APPLICATION INFO.:	US 2001-960716	A1	20010921 (9)

	NUMBER	DATE

PRIORITY INFORMATION: US 2000-234527P 20000922 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Bret E. Field, Bozicevic, Field and Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 16 OF 31 USPATFULL on STN
TI Human hairless gene and protein
AB The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific **binding** molecule, or combinations thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:37655 USPATFULL
TITLE: Human hairless gene and protein
INVENTOR(S): Thompson, Catherine C., Baltimore, MD, UNITED STATES
PATENT ASSIGNEE(S): Carnegie Institution of Washington (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027300	A1	20030206
APPLICATION INFO.:	US 2001-24368	A1	20011221 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-287354, filed on 7 Apr 1999, GRANTED, Pat. No. US 6348348

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80888P	19980407 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 1966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 17 OF 31 USPATFULL on STN
TI Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
AB Disclosed are novel methods of using elongation factor p (**efp**) and related constituents of ribosomal complexes which comprise **efp**, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic elongation factor p and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic elongation factor p.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:26250 USPATFULL
TITLE: Elongation factor P (**EFP**) and assays and antimicrobial treatments related to the same
INVENTOR(S): Marotti, Keith R., Kalamazoo, MI, United States
Poorman, Roger A., Kalamazoo, MI, United States
Wells, Peter A., Kalamazoo, MI, United States
Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-322732, filed on 28 May 1999

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Cochrane Carlson, Karen
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: O'Connor, P.C., Cozen
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 18 OF 31 USPATFULL on STN
TI Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:13200 USPATFULL
TITLE: Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof
INVENTOR(S): Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PATENT ASSIGNEE(S): Human Genome Science, Inc., Rockville, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6506581	B1	20030114
APPLICATION INFO.:	US 2000-557884		20000425 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-476102, filed on 7 Jun

1995 Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Brusca, John S.
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 47 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT: 4510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 19 OF 31 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:346967 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6500922	B1	20021231
APPLICATION INFO.:	US 1997-779599		19970107 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, now patented, Pat. No. US 5708142
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Marschang, Diane L.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 3808
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 20 OF 31 USPATFULL on STN
TI Novel Polynucleotides
AB Novel polynucleotides derived from microorganisms belonging to coryneform bacteria and fragments thereof, polypeptides encoded by the polynucleotides and fragments thereof, polynucleotide arrays comprising the polynucleotides and fragments thereof, recording media in which the nucleotide sequences of the polynucleotide and fragments thereof have been recorded which are readable in a computer, and use of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:343879 USPATFULL
TITLE: Novel Polynucleotides
INVENTOR(S): Nakagawa, Satoshi, Tokyo, JAPAN
Mizoguchi, Hiroshi, Tokyo, JAPAN
Ando, Seiko, Tokyo, JAPAN
Hayashi, Mikiro, Tokyo, JAPAN
Ochiai, Keiko, Tokyo, JAPAN
Yokoi, Haruhiko, Tokyo, JAPAN
Tateishi, Naoko, Tokyo, JAPAN
Senoh, Akihiro, Tokyo, JAPAN

Ikeda, Masato, Tokyo, JAPAN
Ozaki, Akio, Hofu-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002197605	A1	20021226	
APPLICATION INFO.:	US 2000-738626	A1	20001218	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-377484	19991216
	JP 2000-159162	20000407
	JP 2000-280988	20000803

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 13673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 31 USPATFULL on STN
TI Oncolytic/immunogenic complementary-adenoviral vector system
AB This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:259416 USPATFULL
TITLE: Oncolytic/immunogenic complementary-adenoviral vector system
INVENTOR(S): Alemany, Ramon, Grayslake, IL, UNITED STATES
Fang, Xiangming, Libertyville, IL, UNITED STATES
Zhang, Wei-Wei, Libertyville, IL, UNITED STATES
PATENT ASSIGNEE(S): GenStar Therapeutics Corp., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142989	A1	20021003	
APPLICATION INFO.:	US 2002-153329	A1	20020522	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-797160, filed on 10 Feb 1997, GRANTED, Pat. No. US 6403370
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 22 OF 31 USPATFULL on STN

TI Insect expression vectors

AB The invention provides insect shuttle vectors, and methods of using such vectors, for stably transforming disparate insect cell lines to express heterologous proteins. The invention provides a transformed insect cell selection system based on resistance to the bleomycin/phleomycin family of antibiotics, including the antibiotic Zeocin. Efficient promoters derived from baculovirus immediate early promoters are disclosed for use in directing expression of heterologous proteins, including selectable markers, in transformed insect cells of the invention. Transposon-based vectors are disclosed that provide inducible transposition to optimize heterologous protein expression and unobtrusive markers to facilitate selection of desired transformants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:215326 USPATFULL

TITLE: Insect expression vectors

INVENTOR(S): Grigliatti, Tom A., Vancouver, CANADA
Pfeifer, Tom A., Vancouver, CANADA
Theilmann, David A., Summerland, CANADA
Hegedus, Dwayne D., Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002116723	A1	20020822
APPLICATION INFO.:	US 2001-896888	A1	20010629 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-48911, filed on 26 Mar 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1998-2221819	19980128
	US 1997-49946P	19970327 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KLARQUIST SPARKMAN CAMPBELL LEIGH & WHINSTON, LLP, One World Trade Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR, 97204

NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 27 Drawing Page(s)

LINE COUNT: 2853

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 23 OF 31 USPATFULL on STN

TI Oncolytic/immunogenic complementary-adenoviral vector system

AB This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:136814 USPATFULL
TITLE: Oncolytic/immunogenic complementary-adenoviral vector system
INVENTOR(S): Alemany, Ramon, Grayslake, IL, United States
Fang, Xiangming, Libertyville, IL, United States
Zhang, Wei-Wei, Libertyville, IL, United States
PATENT ASSIGNEE(S): GenStar Therapeutics Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403370	B1	20020611
APPLICATION INFO.:	US 1997-797160		19970210 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: McDonnell Boehnen Hulbert & Berghoff
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 24 OF 31 USPATFULL on STN
TI Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
AB Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs and subcellular components. The inventive techniques may be employed in high throughput screening of potential diagnostic and/or therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:105887 USPATFULL
TITLE: Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
INVENTOR(S): Hochman, Daryl W., Bahama, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055092	A1	20020509
	US 6573063	B2	20030603
APPLICATION INFO.:	US 2001-1366	A1	20011030 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-629046, filed on 31 Jul 2000, PATENTED Continuation of Ser. No. US 1999-326008, filed on 4 Jun 1999, PATENTED Continuation-in-part of Ser. No. US 1997-949416, filed on 14 Oct 1997, PATENTED Continuation of Ser. No. US 1995-539296, filed on 4 Oct 1995, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-88494P	19980608 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ann W. Speckman, SPECKMAN LAW GROUP, Suite 100, 1501 Western Avenue, Seattle, WA, 98101
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 2861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 25 OF 31 USPATFULL on STN
TI Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
AB The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:50802 USPATFULL
TITLE: Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
INVENTOR(S): Fleischmann, Robert D., Gaithersburg, MD, United States
Adams, Mark D., N. Potomac, MD, United States
White, Owen, Gaithersburg, MD, United States
Smith, Hamilton O., Towson, MD, United States
Venter, J. Craig, Potomac, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6355450	B1	20020312	
APPLICATION INFO.:	US 1995-476102		19950607	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-426787, filed on 21 Apr 1995, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Campell, Bruce R.
NUMBER OF CLAIMS: 88
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 47 Drawing Figure(s); 47 Drawing Page(s)
LINE COUNT: 4666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 26 OF 31 USPATFULL on STN
TI Human hairless gene and protein
AB The novel nucleotide sequence and deduced amino acid sequence of the human Hairless gene and protein, respectively, are disclosed. A Hairless expression construct may be used in transcription assays. Moreover, processes of making and using the aforementioned products in screening assays which affect Hairless-regulated transcription are disclosed. Kits comprising a polynucleotide, polypeptide, specific **binding** molecule, or combinations thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:34327 USPATFULL
TITLE: Human hairless gene and protein
INVENTOR(S): Thompson, Catherine C., Baltimore, MD, United States
PATENT ASSIGNEE(S): The Carnegie Institution of Washington, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6348348	B1	20020219	
APPLICATION INFO.:	US 1999-287354		19990407	(9)

	NUMBER	DATE

PRIORITY INFORMATION: US 1998-80888P 19980407 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 27 OF 31 USPATFULL on STN
TI Novel compositions and methods of screening for B cell activity modulators
AB The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naive, activated, tolerant and immunosuppressed B cells. The present invention makes possible the identification and characterization of targets useful in prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:182304 USPATFULL
TITLE: Novel compositions and methods of screening for B cell activity modulators
INVENTOR(S): Glynne, Richard, Palo Alto, CA, United States
Goodnow, Chris, Ainslie, ACT, Australia
Mack, Davis, Menlo Park, CA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001031462	A1	20011018	
APPLICATION INFO.:	US 2000-747760	A1	20001221	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-171796P	19991222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Andrew T. Serafini, Ph.D., TOWNSEND AND TOWNSEND AND CREW LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3841
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 28 OF 31 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:19275 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States

Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869612		19990209
APPLICATION INFO.:	US 1996-744139		19961105 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, now patented, Pat. No. US 5708142
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 3799
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 29 OF 31 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAFs. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2) and CD40, and are involved in the mediation of TNF and CD40 ligand biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:42239 USPATFULL
TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741667		19980421
APPLICATION INFO.:	US 1995-446915		19950522 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-331394, filed on 28 Oct 1994, now patented, Pat. No. US 5670319 which is a continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 30 OF 31 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:4740 USPATFULL

TITLE: Tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5708142		19980113
APPLICATION INFO.:	US 1994-250858		19940527 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 3737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 31 OF 31 USPATFULL on STN
TI Assay for tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:86433 USPATFULL
TITLE: Assay for tumor necrosis factor receptor-associated factors
INVENTOR(S): Goeddel, David V., Hillsborough, CA, United States
Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670319		19970923
APPLICATION INFO.:	US 1994-331394		19941028 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Dreger, Ginger R.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 3908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS  4  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS  5  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS  6  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03   FRANCEPAT now available on STN
 NEWS  9  MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29   WPIFV now available on STN
 NEWS 11  MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12  APR 26   PROMT: New display field available
 NEWS 13  APR 26   IFIPAT/IFIUDB/IFICDB: New super search and display field
                   available
 NEWS 14  APR 26   LITALERT now available on STN
 NEWS 15  APR 27   NLDB: New search and display fields available
 NEWS 16  May 10   PROUSDDR now available on STN
 NEWS 17  May 19   PROUSDDR: One FREE connect hour, per account, in both May
                   and June 2004
 NEWS 18  May 12   EXTEND option available in structure searching
 NEWS 19  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20  May 17   FRFULL now available on STN
 NEWS 21  May 27   STN User Update to be held June 7 and June 8 at the SLA 2004
                   Conference
 NEWS 22  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS 23  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS 24  May 27   Explore APOLLIT with free connect time in June 2004

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
```

```
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:36:11 ON 07 JUN 2004

=> file medline, uspatful, dgene, wpids, fsta, biosis, biobusiness
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 18:36:43 ON 07 JUN 2004

FILE 'USPATFULL' ENTERED AT 18:36:43 ON 07 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:36:43 ON 07 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 18:36:43 ON 07 JUN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 18:36:43 ON 07 JUN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 18:36:43 ON 07 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOBUSINESS' ENTERED AT 18:36:43 ON 07 JUN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s elongation factor p or efp
L1          832 ELONGATION FACTOR P OR EFP

=> s l1 and fluorescence
L2           60 L1 AND FLUORESCENCE

=> s l2 and bind?
L3           57 L2 AND BIND?

=> s l3 and binding assay
L4           26 L3 AND BINDING ASSAY

=> s tryptophan
L5       114773 TRYPTOPHAN

=> s l5 and l2
L6           33 L5 AND L2

=> s l6 and l4
L7           21 L6 AND L4

=> d l7 ti abs ibib tot

L7   ANSWER 1 OF 21  USPATFULL on STN
TI     Nucleotide sequences of moraxella catarrhalis genome
AB     The present invention provides the genomic sequences of a library of
       purified, polynucleotides, or their complements, comprising the genome
       of Moraxella catarrhalis. The invention also provides the identification
       of open reading frames contained within the polynucleotides of the
       library. The present invention further provides for the use of the
       polynucleotides, their complements or fragments, and proteins or
       portions thereof for identifying ligands and useful diagnostic and
       therapeutic compositions. In addition the invention provides for
```

vectors, host cell sand methods for producing M. catarrhalis proteins or portions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:88584 USPATFULL		
TITLE:	Nucleotide sequences of moraxella catarrhalis genome		
INVENTOR(S):	Lagace, Robert E., Belmont, CA, UNITED STATES Patterson, Chandra, Menlo Park, CA, UNITED STATES Berg, Kim L., Palo Alto, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067554	A1	20040408
APPLICATION INFO.:	US 2003-672787	A1	20030926 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-596002, filed on 16 Jun 2000, GRANTED, Pat. No. US 6632636		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-140121P	19990618 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3677		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 21 USPATFULL on STN

TI Methods of identifying modulators of bromodomains

AB The present invention provides the structural determination of a bromodomain determined by NMR spectroscopy. The present invention also provides **binding** partners for the bromodomain. The present invention further provides the structural determination of the Tat-P/CAF **binding** complex determined by NMR spectroscopy. In addition, the present invention provides methodology for related drug discovery using high throughput drug screening or structure based rational drug design using the three-dimensional data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:57376 USPATFULL		
TITLE:	Methods of identifying modulators of bromodomains		
INVENTOR(S):	Zhou, Ming-Ming, Greenwich, CT, UNITED STATES Aggarwal, Aneel K., Edgewater, NJ, UNITED STATES Verdin, Eric, San Francisco, CA, UNITED STATES Ott, Melanie, San Francisco, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043378	A1	20040304
APPLICATION INFO.:	US 2001-784553	A1	20010216 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 510314, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	31574		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 21 USPATFULL on STN

TI Novel proteins and nucleic acids encoding same

AB The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically **bind** to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:39248 USPATFULL

TITLE: Novel proteins and nucleic acids encoding same

INVENTOR(S): Anderson, David W., Branford, CT, UNITED STATES
Berghs, Constance, New Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Catterton, Elina, Madison, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Jeffers, Michael E., Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004029789	A1	20040212	
APPLICATION INFO.:	US 2002-188186	A1	20020702	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-303046P	20010705	(60)
	US 2002-360814P	20020301	(60)
	US 2001-303828P	20010709	(60)
	US 2001-323380P	20010919	(60)
	US 2002-361133P	20020301	(60)
	US 2001-304016P	20010709	(60)
	US 2001-304502P	20010711	(60)

	US 2001-305262P	20010713 (60)
	US 2002-373881P	20020419 (60)
	US 2001-305673P	20010716 (60)
	US 2001-323969P	20010921 (60)
	US 2002-372326P	20020412 (60)
	US 2002-361677P	20020305 (60)
	US 2002-345022P	20020104 (60)
	US 2002-363637P	20020312 (60)
	US 2002-373921P	20020419 (60)
	US 2001-307536P	20010724 (60)
	US 2002-360830P	20020301 (60)
	US 2001-306085P	20010717 (60)
	US 2001-308228P	20010727 (60)
	US 2002-372990P	20020416 (60)
	US 2002-361147P	20020301 (60)
	US 2001-308877P	20010730 (60)
	US 2002-345038P	20020104 (60)
	US 2002-361172P	20020228 (60)
	US 2001-313328P	20010817 (60)
	US 2001-318711P	20010912 (60)
	US 2001-309255P	20010801 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 23357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 21 USPATFULL on STN
TI Methods of identifying modulators of bromodomains
AB The present invention provides the structural determination of a bromodomain determined by NMR spectroscopy. The present invention also provides **binding** partners for the bromodomain. The present invention further provides the structural determination of the Tat-P/CAF **binding** complex determined by NMR spectroscopy. In addition, the present invention provides methodology for related drug discovery using high throughput drug screening or structure based rational drug design using the three-dimensional data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:13093 USPATFULL
TITLE: Methods of identifying modulators of bromodomains
INVENTOR(S): Zhou, Ming-Ming, Greenwich, CT, UNITED STATES
Aggarwal, Aneel K., Edgewater, NJ, UNITED STATES
Verdin, Eric, San Francisco, CA, UNITED STATES
Ott, Melanie, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009613	A1	20040115
APPLICATION INFO.:	US 2002-209201	A1	20020731 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-784553, filed on 16 Feb 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Page(s)
LINE COUNT: 3719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 21 USPATFULL on STN
TI Nucleic acids encoding 3-ketoacyl-ACP reductase from Moraxella catarrahalis
AB The present invention provides the genomic sequences of a library of purified nucleic acid molecules, or their complements, comprising the genome of Moraxella catarrhalis. The invention also provides the identification of open reading frames contained within the nucleic acid molecules of the library. The present invention further provides for the use of the nucleic acid molecules, their complements or fragments, and proteins or portions thereof for identifying ligands and useful diagnostic and therapeutic compositions. In addition the invention provides for vectors, host cells and methods for producing M. catarrhalis proteins or portions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:273341 USPATFULL		
TITLE:	Nucleic acids encoding 3-ketoacyl-ACP reductase from Moraxella catarrahalis		
INVENTOR(S):	Lagace, Robert E., Belmont, CA, United States Patterson, Chandra, Menlo Park, CA, United States Berg, Kim L., Palo Alto, CA, United States		
PATENT ASSIGNEE(S):	Elitra Pharmaceuticals Inc., San Diego, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632636	B1	20031014
APPLICATION INFO.:	US 2000-596002		20000616 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1999-140121P		19990618 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear, LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	3135		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 21 USPATFULL on STN
TI Staphylococcus aureus genes and polypeptides
AB The present invention relates to novel genes from S. aureus and the polypeptides they encode. Also provided as are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypeptide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:265349 USPATFULL		
TITLE:	Staphylococcus aureus genes and polypeptides		
INVENTOR(S):	Bailey, Camella, Washington, DC, UNITED STATES Choi, Gil H., Rockville, MD, UNITED STATES		
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)		
	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186364	A1	20031002
APPLICATION INFO.:	US 2002-138701	A1	20020506 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-512255, filed on 24 Feb 2000, GRANTED, Pat. No. US 6403337 Continuation-in-part of Ser. No. WO 1999-US19726, filed on 31 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1997-956171, filed on 20 Oct 1997, GRANTED, Pat. No. US 6593114 Continuation-in-part of Ser. No. US 1997-781986, filed on 3 Jan 1997, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98964P	19980901 (60)
	US 1996-9861P	19960105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 9244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 21 USPATFULL on STN
TI Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Enterococcus faecalis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:240330 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
INVENTOR(S): Doucette-Stamm, Lynn A., 14 Flanagan Dr., Framingham, MA, United States 01701
Bush, David, 205 Holland St., Somerville, MA, United States 02144

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6617156	B1	20030909
APPLICATION INFO.:	US 1998-134000		19980813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-55778P	19970815 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mosher, Mary E.
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1,5,14
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 13738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 21 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated

factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:174195 USPATFULL
TITLE:	Tumor necrosis factor receptor-associated factors
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, UNITED STATES Rothe, Mike, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S):	Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003120043	A1	20030626
APPLICATION INFO.:	US 2002-283500	A1	20021030 (10)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-779599, filed on 7 Jan 1997, GRANTED, Pat. No. US 6500922 Continuation of Ser. No. US 1996-744139, filed on 5 Nov 1996, GRANTED, Pat. No. US 5869612 Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, GRANTED, Pat. No. US 5708142
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Page(s)
LINE COUNT:	3788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 21 USPATFULL on STN

TI Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics

AB The invention provides isolated polypeptide and nucleic acid sequences derived Enterococcus faecium that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:169096 USPATFULL
TITLE:	Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
INVENTOR(S):	Doucette-Stamm, Lynn A., Framingham, MA, United States Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S):	Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6583275	B1	20030624
APPLICATION INFO.:	US 1998-107532		19980630 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-85598P	19980514 (60)
	US 1997-51571P	19970702 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Marschel, Ardin H.
LEGAL REPRESENTATIVE:	Genome Therapeutics Corporation

NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 15265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 21 USPATFULL on STN
TI Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Acinetobacter mirabilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:130010 USPATFULL
TITLE: Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
INVENTOR(S): Breton, Gary, Marlborough, MA, United States
Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6562958	B1	20030513	
APPLICATION INFO.:	US 1999-328352		19990604	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-88701P	19980609	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Borin, Michael
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 16618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 21 USPATFULL on STN
TI MCEF, a novel transcription factor
AB A novel protein, MCEF, antibodies thereto, nucleic acid sequences that code for it, and probes for leukemia-associated translocation junctions; also process of using MCEF or other P-TEFb proteins such as CDC37, and HSP-90 to identifv reagents promoting dissociation of those proteins from each other or inhibiting their association and to discover anti-HIV reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:57094 USPATFULL
TITLE: MCEF, a novel transcription factor
INVENTOR(S): Estable, Mario, Toronto, CANADA
Roeder, Robert A., New York, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003039658	A1	20030227	
APPLICATION INFO.:	US 2001-932257	A1	20010817	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226340P	20000818 (60)
	US 2000-226339P	20000818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 21 USPATFULL on STN
TI **Elongation factor P** (**EFP**) and assays and antimicrobial treatments related to the same
AB Disclosed are novel methods of using **elongation factor p** (**efp**) and related constituents of ribosomal complexes which comprise **efp**, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compounds which modulate prokaryotic **elongation factor p** and modify cell function are described. Both in vitro and in vivo methods for identifying compounds which modulate such constituents and affect cell function are described. Such identified compounds, including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compounds, and antiseptics containing such compounds are described. The present invention is also directed to methods and compounds that modulate prokaryotic **elongation factor p**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:26250 USPATFULL
TITLE: **Elongation factor P** (**EFP**) and assays and antimicrobial treatments related to the same
INVENTOR(S): Marotti, Keith R., Kalamazoo, MI, United States
Poorman, Roger A., Kalamazoo, MI, United States
Wells, Peter A., Kalamazoo, MI, United States
Shinabarger, Dean L., Portage, MI, United States
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511813	B1	20030128
APPLICATION INFO.:	US 2000-704321		20001102 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-322732, filed on 28 May 1999

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117473P	19990127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Cochrane Carlson, Karen
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: O'Connor, P.C., Cozen
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 21 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:346967 USPATFULL
TITLE:	Tumor necrosis factor receptor-associated factors
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, United States Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6500922	B1	20021231
APPLICATION INFO.:	US 1997-779599		19970107 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, now patented, Pat. No. US 5708142
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Ulm, John
LEGAL REPRESENTATIVE:	Marschang, Diane L.
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT:	3808

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 21 USPATFULL on STN
TI Novel Polynucleotides
AB Novel polynucleotides derived from microorganisms belonging to coryneform bacteria and fragments thereof, polypeptides encoded by the polynucleotides and fragments thereof, polynucleotide arrays comprising the polynucleotides and fragments thereof, recording media in which the nucleotide sequences of the polynucleotide and fragments thereof have been recorded which are readable in a computer, and use of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:343879 USPATFULL
TITLE:	Novel Polynucleotides
INVENTOR(S):	Nakagawa, Satoshi, Tokyo, JAPAN Mizoguchi, Hiroshi, Tokyo, JAPAN Ando, Seiko, Tokyo, JAPAN Hayashi, Mikiro, Tokyo, JAPAN Ochiai, Keiko, Tokyo, JAPAN Yokoi, Haruhiko, Tokyo, JAPAN Tateishi, Naoko, Tokyo, JAPAN Senoh, Akihiro, Tokyo, JAPAN Ikeda, Masato, Tokyo, JAPAN Ozaki, Akio, Hofu-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002197605	A1	20021226	
APPLICATION INFO.:	US 2000-738626	A1	20001218	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-377484	19991216

	JP 2000-159162 20000407
	JP 2000-280988 20000803
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
NUMBER OF CLAIMS:	68
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	13673

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 21 USPATFULL on STN

TI Staphylococcus aureus genes and polypeptides

AB The present invention relates to novel genes from S. aureus and the polypeptides they encode. Also provided as are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypeptide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:136784 USPATFULL
TITLE:	Staphylococcus aureus genes and polypeptides
INVENTOR(S):	Bailey, Camella, Washington, DC, United States Choi, Gil H., Rockville, MD, United States
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403337	B1	20020611
APPLICATION INFO.:	US 2000-512255		20000224 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1999-US19726, filed on 31 Aug 1999 Continuation-in-part of Ser. No. US 1997-956171, filed on 20 Oct 1997 Continuation-in-part of Ser. No. US 1997-781986, filed on 3 Jan 1997 Continuation-in-part of Ser. No. US 1997-781986, filed on 5 Jan 1997 Continuation-in-part of Ser. No. US 1997-781986, filed on 5 Jan 1997

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Brusca, John S.
LEGAL REPRESENTATIVE:	Human Genome Sciences, Inc.
NUMBER OF CLAIMS:	65
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	6784

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 21 USPATFULL on STN

TI Novel compositions and methods of screening for B cell activity modulators

AB The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are provided for differing states of B cells, including resting, naive, activated, tolerant and immunosuppressed B cells. The present invention makes possible the identification and characterization of targets useful in

prognosis, diagnosis, monitoring, rational drug design, and/or therapeutic intervention of immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:182304 USPATFULL		
TITLE:	Novel compositions and methods of screening for B cell activity modulators		
INVENTOR(S):	Glynne, Richard, Palo Alto, CA, United States Goodnow, Chris, Ainslie, ACT, Australia Mack, Davis, Menlo Park, CA, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001031462	A1	20011018
APPLICATION INFO.:	US 2000-747760	A1	20001221 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1999-171796P		19991222 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Andrew T. Serafini, Ph.D., TOWNSEND AND TOWNSEND AND CREW LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA, 94111-3834		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	3841		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 21 USPATFULL on STN

TI Tumor necrosis factor receptor-associated factors

AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:19275 USPATFULL		
TITLE:	Tumor necrosis factor receptor-associated factors		
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, United States Rothe, Mike, San Mateo, CA, United States		
PATENT ASSIGNEE(S):	Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869612		19990209
APPLICATION INFO.:	US 1996-744139		19961105 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-250858, filed on 27 May 1994, now patented, Pat. No. US 5708142		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3799		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 21 USPATFULL on STN

TI Tumor necrosis factor receptor-associated factors

AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAFs. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2) and CD40, and are involved in the mediation of TNF and CD40 ligand biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:42239 USPATFULL		
TITLE:	Tumor necrosis factor receptor-associated factors		
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, United States Rothe, Mike, San Mateo, CA, United States		
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741667		19980421
APPLICATION INFO.:	US 1995-446915		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-331394, filed on 28 Oct 1994, now patented, Pat. No. US 5670319 which is a continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4348		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 21 USPATFULL on STN
TI Tumor necrosis factor receptor-associated factors
AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:4740 USPATFULL		
TITLE:	Tumor necrosis factor receptor-associated factors		
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, United States Rothe, Mike, San Mateo, CA, United States		
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5708142		19980113
APPLICATION INFO.:	US 1994-250858		19940527 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Dreger, Ginger R.		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3737		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 21 USPATFULL on STN
TI Assay for tumor necrosis factor receptor-associated factors

AB The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:86433 USPATFULL
TITLE:	Assay for tumor necrosis factor receptor-associated factors
INVENTOR(S):	Goeddel, David V., Hillsborough, CA, United States Rothe, Mike, San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670319		19970923
APPLICATION INFO.:	US 1994-331394		19941028 (8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-250858, filed on 27 May 1994
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Ulm, John
LEGAL REPRESENTATIVE:	Dreger, Ginger R.
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT:	3908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 21 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Identifying a compound which modulates the activity of prokaryotic **elongation factor p** (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.

AN 2000-524303 [47] WPIDS

AB WO 200045177 A UPAB: 20000925

NOVELTY - A method (M1) for identifying a compound which modulates the activity of **efp** comprises contacting **efp** with a compound and determining whether the compound modifies activity of **efp**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell containing **efp** with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a composition comprising **efp**, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to **bind** to a complex formed through the interaction of **efp**, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound **binds** to **efp**

in association with the 30S subunit or 70S ribosome or interferes with the **binding** of **efp** and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates **efp** activity comprising:

(a) contacting **efp** with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates **efp** activity comprising:

(a) contacting a cell or composition containing **efp** with a detectably labelled oxazolidinone compound known to **bind** **efp**;

(b) contacting the composition or cell with an unlabelled compound; and

(c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates **efp** but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic **efp** by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic **efp**, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the **efp** or cell or cell preparation containing the **efp** , the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS
DOC. NO. NON-CPI: N2000-387540
DOC. NO. CPI: C2000-155724
TITLE: Identifying a compound which modulates the activity of prokaryotic **elongation factor** **p** (**efp**) for screening for compounds which can be used as antibiotics comprises contacting **efp** with a compound and determining if **efp** activity is modified.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN; (PHAA) PHARMACIA & UPJOHN CO
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW

US 097134250SP1

Creation date: 06-10-2004
Indexing Officer: SUK - SOPHY UK
Team: OIPEBackFileIndexing
Dossier: 09713425

Legal Date: 06-10-2004

No.	Doccode	Number of pages
1	CTFR	7
2	1449	11
3	SRFW	1
4	FWCLM	1

Total number of pages: 20

Remarks:

Order of re-scan issued on .....